(Q38258537)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

chronic obstructive pulmonary disease

20 February 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Luigino Calzetta

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Maria Gabriella Matera

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mario Cazzola

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

1 November 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1983-1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

Phosphodiesterase inhibitors in the treatment of inflammatory diseases.

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Efficacy of roflumilast in the COPD frequent exacerbator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Hyperinflation, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Airway and systemic inflammation and decline in lung function in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Corticosteroids: the drugs to beat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

PDE4 inhibitors: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Selective PDE inhibitors as novel treatments for respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Tetomilast: new promise for phosphodiesterase-4 inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Discovery of a novel orally active PDE-4 inhibitor effective in an ovalbumin-induced asthma murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Advances in targeting cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Are phosphodiesterase 4 inhibitors just more theophylline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Phosphodiesterase inhibitors in airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Dual PDE 3/4 inhibition: a novel approach to airway disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

New methods for the discovery and synthesis of PDE7 inhibitors as new drugs for neurological and inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Does sildenafil also improve breathing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

PDE1 isozymes, key regulators of pathological vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Effects of KF19514, a phosphodiesterase 4 and 1 Inhibitor, on bronchial inflammation and remodeling in a murine model of chronic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

AKAPs: the architectural underpinnings of local cAMP signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0303-8

Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

21 January 2018

1 reference

12 December 2020

Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD

1 reference

12 December 2020

The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients.

1 reference

12 December 2020

Physiological effects of roflumilast at rest and during exercise in COPD

1 reference

12 December 2020

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

1 reference

12 December 2020

Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives

1 reference

12 December 2020

In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor

1 reference

12 December 2020

Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD

1 reference

12 December 2020

Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone

1 reference

12 December 2020

Phosphodiesterases maintain signaling fidelity via compartmentalization of cyclic nucleotides

1 reference

12 December 2020

AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).

1 reference

12 December 2020

Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis

1 reference

12 December 2020

10.1007/S40265-014-0303-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

20 February 2020

1022318520

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25300411%20AND%20SRC:MED&resulttype=core&format=json